Global Scans · Pharmaceuticals · Weekly Summary

• [New] Some 12% of Americans are taking a GLP-1 drug, helping convince millions of users and the many people who have watched their transformation that the key to health, beauty and longevity might come in a syringe. Bloomberg
• [New] Injectable GLP-1 drugs turned Novo Nordisk and Eli Lilly into two of the most important pharmaceutical companies in the world, but injections were always going to limit adoption for some patients. Windows Forum
• [New] In 2026, total prescription drug spending growth is expected to slow to a rate of 5.1% due to Inflation Reduction Act provisions. Fortunly
• [New] Drug-resistant infections could contribute to 39 million deaths in the coming decades if effective interventions are not implemented. Innovation News Network
• [New] Axios reports next month's weight-loss drug coverage program may unleash pent-up demand for Wegovy, Zepbound and other treatments, even as clinicians warn they do not have the staffing to absorb a prescribing rush. MM+M - Medical Marketing and Media
• [New] European marketing authorisation is expected within weeks, and a US pivotal trial has been initiated with first data due in 2027 and a New Drug Application planned for 2028. Business of Cannabis
• [New] Without broader investment in manufacturing capacity and R&D, Chile's pharmaceutical export base will remain narrow and structurally constrained. Fitch Solutions
• [New] Although there have been evolving treatment options, including a recently accelerated approval by the U.S. Food and Drug Administration, or FDA, of dordaviprone, the typical estimated survival post-diagnosis is a mere 9 to 15 months, and only 30% of patients are expected to live a full year. SenCanada
• MIT researchers have demonstrated a low-cost design of specialized electronic nozzles, called triaxial electrospray emitters, that could be used to manufacture time-release drug-delivery particles or self-healing materials efficiently and at scale. MIT News | Massachusetts Institute of Technology
• The FDA recently released a warning letter alerting life science orgs to the risks of using and advising against overreliance on AI in drug manufacturing. Forrester
• Opdivo, with $7.1 billion in sales, is expected to lose patent protection in 2028 alongside Keytruda, creating a second major PD-1 checkpoint inhibitor biosimilar opportunity. Life Science Daily News
• The investment case is equally staggering: action on infection prevention, water and sanitation, vaccination and responsible drug prescribing could avert 110 million AMR associated deaths and yield $1 trillion in economic gains by 2050. Health Policy Watch
• Psilocybin is positioned to record the fastest CAGR in the drug type segment from 2026 through 2035 owing to the data emerging from Phase 2 and Phase 3 trials across multiple indications globally. Yahoo Finance Singapore
• The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the Trump administration toward possible approval of the experimental treatments. Fortune
• Across pharma, expirations of major patents between 2025 and 2030 are expected to open more than $300 billion in revenues to generic or biosimilar competition () (). IntuitionLabs
• Leading Drug Class: Anti-VEGF agents are expected to dominate with approximately 72% share in 2026, reflecting their established first-line clinical standard-of-care status for neovascular AMD, diabetic macular edema, and retinal vein occlusion across all major markets. Persistence Market Research
• Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027. Yahoo Finance

Last updated: 30 June 2026